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Abstract
Background: Exchange transfusion (ET) has remained a controversial adjunct therapy for the treatment of severe
malaria. In order to assess the relative contribution of ET to parasite clearance in severe malaria, all patients
receiving ET as an adjunct treatment to parenteral quinine or to artesunate were compared with patients treated
with parenteral treatment with quinine or artesunate but who did not receive ET. ET was executed using a
standardized manual isovolumetric exchange protocol.
Methods: All patients in the Rotterdam Malaria Cohort treated for severe P. falciparum malaria at the Institute for
Tropical Diseases of the Harbour Hospital between 1999 and 2011 were included in this retrospective follow-up
study. Both a two-stage approach and a log-linear mixed model approach were used to estimate parasite clearance
times (PCTs) in patients with imported malaria. Severe malaria was defined according to WHO criteria.
Results: A total of 87 patients with severe malaria was included; 61 received intravenous quinine, whereas 26
patients received intravenous artesunate. Thirty-nine patients received ET as an adjunct treatment to either quinine
(n = 23) or artesunate (n = 16). Data from 84 of 87 patients were suitable for estimation of parasite clearance rates.
PCTs were significantly shorter after administration of artesunate as compared with quinine. In both models, ET did
not contribute significantly to overall parasite clearance.
Conclusion: Manual exchange transfusion does not significantly contribute to parasite clearance in artesunate-
treated individuals. There may be a small effect of ET on parasite clearance under quinine treatment. Institution of
ET to promote parasite clearance in settings where artesunate is available is not recommended, at least not with
manually executed exchange procedures.
Background
European travellers returning from malaria-endemic
areas are at increased risk of developing severe malaria.
If left untreated, the disease can evolve rapidly into a
life-threatening disease with a near to 100% case-fatality
rate [1]. Until the year 2008, severe malaria was treated
with intravenous quinine, a cinchona alkaloid which has
potentially serious adverse effects. After the superior
outcome of artesunate over quinine for the treatment of
severe Plasmodium falciparum malaria became apparent
in two large field trials in Asia and Africa [2,3],
artesunate is also increasingly used for treating severe
malaria in travellers from non-endemic countries [4],
even though the discussion whether artesunate is also
superior over quinine in non-immune travellers has not
been settled yet [5].
In circumstances where optimal anti-malarial and
supportive treatment is available, severe P. falciparum
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malaria in industrialized countries is still associated with
a case-fatality rate of up to 10% [6]. In an effort to fur-
ther reduce the mortality of severe malaria, exchange
transfusion (ET) is often used as an adjunct therapy to
reduce parasite load in cases of high parasitaemia. Be-
sides direct removal of parasitized red cells, ET also im-
proves blood viscosity by removal of uninfected red cells
with reduced deformability, thereby reducing microcir-
culatory sludging and improving oxygen-carrying cap-
acity [7]. Furthermore, ET additionally aims at removing
parasitic antigens and toxic products and correction of
severe anaemia. Although numerous cases in which ET
was successfully used have been described, its use re-
mains controversial mainly because randomized con-
trolled trials have not been performed. Some researchers
have cautioned against the use of ET, given the lack of
conclusive scientific evidence for a survival benefit and
the associated risks of fluid overload, transfusion reac-
tions and potential transmission of blood-borne infec-
tions [8]. Much of the arguments against ET also apply
to transfusion for anaemia, which is nevertheless often
required during the course of severe malaria. On the
other hand, many cases of survival from high parasit-
aemia that were successfully treated with anti-malarials
alone have been documented in the literature [9-14].
In 1998, ET was added to the standard of care for pa-
tients with severe malaria at the Institute for Tropical
Diseases of the Harbour Hospital in Rotterdam, with
additional selection criteria over the WHO criteria for
severe malaria (see below). Given the low case-fatality
rate of severe malaria since then, the ET selection
criteria and exchange protocol remained virtually un-
changed except for replacing quinine by artesunate as
the parenteral anti-malarial treatment of choice since
2008. The mainstay of treatment of severe malaria is a
rapid reduction of parasite biomass. Since quinine and
artesunate both induce parasite elimination but at differ-
ent rates, the relative contribution of ET to parasite
clearance is unknown. In the present study the contribu-
tion of ET to parasite clearance was examined by study-
ing patients receiving intravenous quinine or artesunate
only as well as patients who received ET as an adjunctive
treatment on top of treatment with either intravenous
quinine or artesunate.
Methods
Patients
All patients in the Rotterdam Malaria Cohort treated for
severe P. falciparum malaria at the Institute for Tropical
Diseases of the Harbour Hospital between 1999 and
2011 were included in this retrospective follow-up study.
All patients were diagnosed with imported P. falciparum
malaria and received intravenous anti-malarial treatment
and - when indicated - ET in a well-equipped intensive
care unit (ICU). In order to assess the relative contribu-
tion of ET to parasite clearance in (severe) malaria, all
patients receiving ETas an adjunct treatment to parenteral
quinine or to artesunate were compared with patients
treated with parenteral treatment with quinine or arte-
sunate but who did not receive ET. In 2008, artesunate be-
came available in the Netherlands and replaced quinine as
the treatment of choice for severe malaria. Therefore, four
treatment groups could be discerned. Group I (Quinine
only) consisted of malaria patients receiving quinine with-
out ET. Group II (Artesunate only) consisted of malaria
patients receiving artesunate mono-therapy. Group III
(Quinine + ET) consisted of malaria patients receiving ET
as an adjunct treatment to parenteral treatment with quin-
ine., whereas group IV (Artesunate + ET) consisted of
malaria patients who received artesunate plus ET. In order
to properly evaluate the parasite clearance in relation to
treatment mode, of each malaria patient, demographic,
clinical, and laboratory data were collected using a stan-
dardized case report form after de-identification of indi-
vidual patient data.
Laboratory examinations
Malaria was diagnosed following standard procedures
that comprise quantitative buffy coat (QBC) analysis, a
rapid diagnostic test (RDT) targeting Histidine Rich Pro-
tein II (Binax NOWW Malaria Test,Binax, Inc, Maine,
USA), and microscopic examination of thick and thin
blood smears prepared from freshly collected blood
specimens from finger punctures. Thick blood smears
were stained with Field’s stain (Brunschwig Chemie,
Amsterdam, the Netherlands) and thin smears were
fixed with absolute methanol for 3 minutes and stai-
ned with Diff Quick (Medion Diagnostics, Düdingen,
Switzerland). Parasite density was expressed as the num-
ber of P. falciparum trophozoites per 100 red blood cells
(RBCs) in a thin film or the number of parasites per 100
white blood cells (WBCs) in a thick film. The parasite
load (asexual parasites per microlitre) was calculated
from these figures using the actual WBC and RBC
counts. Other laboratory examinations included haem-
atocrit (Hct), platelet (PLT) count, serum electrolytes
and creatinine, liver enzymes and total bilirubin, blood
glucose and plasma lactate, as described previously [15].
Additional investigations were initiated according to the
clinical judgement of the attending staff.
Definitions
Severe malaria
Patients were considered having severe P. falciparum
malaria if they met predefined criteria for severe malaria
as published previously [1].
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Exchange transfusion
Patients were considered candidates for ET if they met
one of the following additional criteria [16]:
 Parasitaemia of more than 10% infected RBCs
 Presence of schizonts in peripheral blood
 Indication of organ damage (serum creatinine >
250 μmol/L; systolic pressure < 80 mm Hg with cold
extremities; Glasgow Coma Scale of less than 12;
convulsions; pulmonary oedema; serum bilirubin >
50 μmol/L)
 Acidaemia (pH < 7.25)
 Diffuse intravascular coagulation
 Haemoglobinuria
Parasite clearance times
Parasite clearance time (PCT) 50%, PCT 90%, PCT 95%,
PCT 99% were defined as the time (in hours) to obtain a
50%, 90%, 95%, 99% reduction in parasite burden after
start of the treatment, respectively. T = 0 was defined as
the time point at which the first dose of parenteral anti-
malarial treatment was given.
Treatment
Quinine
Quinine dihydrochloride (magistral preparation) was ad-
ministered intravenously with an initial loading dose of
20 mg/kg (maximum 1,800 mg) infused over 4 hours
(in 500 mL of 5% dextrose in water), followed by 10 mg/
kg infused over 8 hours three times a day (maximum
1,800 mg/day) until starting oral therapy.
Artesunate
Artesunate (Malacef 60™, ACE Pharmaceuticals, Zeewolde,
the Netherlands) was given intravenously in a dose of
2.4 mg/kg on T = 0, 12 and 24 hours later and then daily
thereafter until the patient could tolerate oral medication.
Exchange transfusion
ET was performed using a manual isovolumetric ap-
proach as described previously [16]. The ET procedure
was initiated as soon as indications of organ dysfunction
or hyperparasitaemia became apparent. After admission
to the ICU, a large-bore cannula was inserted in the right
antecubital vein, which was used to transfuse fresh RBCs
and plasma (the ‘in-flow’ tract). A second large-bore ven-
ous catheter was inserted into the antecubital vein of the
opposite arm, which was used to collect blood into a
donor set (the ‘out-flow’ tract). One unit of leukocyte
depleted donor RBCs (approximate volume 270–290 ml,
Haematocrit 0.5 – 0.65, Sanquin, Amsterdam) and 1 unit
of donor fresh-frozen plasma (FFP, volume approximately
310 ml, Sanquin, Amsterdam) were given in 1 hour via
the in-flow catheter; the rate of inbound blood transfusion
was controlled to approximate the blood extracted from
the out-flow catheter. In order to prevent volume overload
particular care was given to retain an isovolumetric bal-
ance. The clinical exchange procedure aimed at initial ex-
change of half the estimated blood volume (~ 2.5 L) by
extraction of 5 times 0.5 L whole blood from the patient
and simultaneous administration of 5 units of RBCs and 4
units of fresh frozen plasma FFP after which residual para-
sitaemia was measured. When the parasite count had
dropped below the level of 5% infected RBCs, the ex-
change procedure was discontinued; when the circulating
parasite load remained above 10% infected RBCs, a
complete procedure (5 RBCs plus 4 FFPs) was repeated; a
partial exchange procedure (3 RBCs plus 2 FFPs) was exe-
cuted when evaluation revealed a residual parasite load be-
tween 5 and 10% infected RBCs. Central venous pressure,
blood pressure, pulse rate, oxygen saturation and urine
output were monitored frequently during the ET proced-
ure, which always took place at a well-equipped ICU.
Estimation of parasite clearance times
Both a two-stage approach [17] and log-linear mixed ef-
fects modelling [18] were used to estimate parasite clear-
ance times. The two-stage approach estimates individual
parameters by fitting the parasite count versus time
curve of each patient separately using the parasite clear-
ance estimator provided by the WorldWide Antimalaria
Resistance Network (WWARN) [17]. The population
mean and variance are derived from these data [19]. This
model may have a limited degree of precision when indi-
vidual data are sparse. The fewer measurements per in-
dividual, the greater the estimation error which may
have a profound influence on parameter estimates [20].
Furthermore, no weighting of individual data is done. In
heterogeneous data sets not all individuals have the
same number of measurements and some individual‘s
parameters may be estimated more precisely than those
of others [21]. Since this imbalance is not taken into ac-
count in the subsequent analysis, inter-individual vari-
ability tends to be overestimated [22].
To account for these imitations, the data were also
analysed with a population model. With population
modelling, such as with linear mixed models, all data
from the entire population are analysed simultaneously,
while still taking into account the correlation in the data,
i.e. grouping the observations from individual patients
[19]. It additionally allows for analysis of heterogeneous
data (sparse and/ or imbalanced) while identifying and
estimating both inter- and intra-individual variability
[23]. It has the principal advantage of yielding a true
“mean data curve” whereas the two-stage model ap-
proach only produces the mean of a series of individual
curves. The time course of the parasite count was fitted
to a mono-exponential elimination model as previously
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described [18]. A log-linear mixed effects model, esti-
mating the initial parasite count and the parasite elimin-
ation rate, was generated using restricted maximum
likelihood method. Based on the estimates of this model,
the time to 50% (PCT50), 90% (PCT90), 95% (PCT95) and
99% (PCT99) clearance of the parasites was calculated.
Treatment mode (artesunate or quinine), exchange
transfusion (yes or no) and time were entered as ex-
planatory variables, including the interaction between
treatment and time and between exchange transfusion
and time. To account for the repeated measurements,
intercepts and slopes were allowed to change over
patients. Linear mixed effects modeling was done on the
logarithmic values of the parasite count using the
MIXED function in SPSS.
In this study, both methods were used to estimate the
role of exchange transfusion in parasite clearance since
the WWARN model has recently been promoted as the
method of choice for estimating parasite clearance [17].
Although both methods demonstrated the same trend,
the mixed model yields a more precise estimate of inter-
individual variability than the traditional two-stage
approach, especially in heterogeneous observational
datasets [23] as in the present study and, therefore,
the results of the mixed model were preferred and
shown in the main text. For reasons of clarity, the
data of the two-stage approach (WWARN model) are
given in Additional file 1.
Statistics
All analyses were done with software SPSS version 18.0
(IBM Inc., Chicago, IL).
Demographic data, clinical presentations and outcome
were compared between patients who were treated with
quinine or artesunate alone and patients who received
ET adjunctive to quinine or artesunate using Kruskal-Wallis
test for non-parametric comparisons followed by Dunn.
Since patients receiving exchange transfusion are more
likely to present with more severe disease, statistical
comparisons focused on comparisons of groups with
comparable disease severity (e.g. comparing quinine +
ET (group III) with artesunate + ET (group IV) and
comparing quinine only (group I) with artesunate only
(group II) on the other hand) with the use of non-
parametric Mann–Whitney test. A p-value of less than
0.05 was considered significant.
Ethical considerations
Given the retrospective observational design of this
study, ethical approval of this study was not required,
according to the Dutch Medical Research Involving
Human Subjects Act.
Results
Patient characteristics
A total of 87 patients with severe malaria were included in
this study; 61 received i.v. quinine, whereas 26 patients
received i.v. artesunate. Thirty-nine patients received ET
as an adjunct treatment to either quinine (n = 23) or
artesunate (n = 16). As shown in Table 1, almost half
(43 %) of the patients were non-immune European travel-
lers. Most patients acquired their P. falciparum infection
in West Africa and had not used chemoprophylaxis. Fifty-
six patients (64%) were classified with severe malaria
(one or more WHO criteria), the remaining 31 patients
were given parenteral anti-malarial (24 received quinine
while seven received artesunate monotherapy) because
parasitaemia was between 2-5%, which is the per-protocol
treatment policy at the Harbour hospital of Rotterdam.
Patients receiving ET presented with more severe disease
(including significantly higher parasitaemia) as compared
with malaria patients not receiving ET (Table 1), in line
with the clinical treatment algorithm. Among patients re-
ceiving ET, there was no difference between those treated
with quinine and those treated with artesunate with regard
to demographic data, ethnicity, continent of acquisition,
vital signs on admission, laboratory data on admission or
outcome (Table 1). Patients treated with artesunate
monotherapy (group II) only differed from patients treated
with quinine monotherapy (group I) in duration of
hospitalization (4.4 ±1.1 days versus 6.9 ± 2.3 days respect-
ively, p-value 0.0006).
Parasite clearance times
The crude parasite count of the 87 malaria patients and
the parasite clearance in relation to time and treatment
are shown in Figure 1. Data from 84 of 87 patients were
suitable for estimation of parasite clearance rates. Three
patients were excluded from fitting; one patient because
the initial parasitaemia was too low (quinine, group I)
and two others (one from the artesunate group II and
one from quinine + ET group III) because the last para-
site count was too high. Log-transformed data from the
remaining 84 patients were fitted to a linear model and
had a minimum of 4 data points. The detection limit
was set at 16 (in 93% of patients) or 10 (in 7% of pa-
tients) parasites per microlitre. In six patients (three
from the quinine plus ET treatment group (III), two
from the artesunate group (II) and one from the
artesunate plus ET group (IV)), a lag phase was identi-
fied with a median (IQR, range) duration of 9 (8.55-
9.075; 4–9.5) hours. A tail, suggesting a second parasite
clearance rate constant, was present in two patients
from the quinine treatment group (I), while no outliers
were identified.
The findings of the mixed effects model evaluating the
effect of time (as a fixed effect) and treatment mode, ET
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and their interaction (random effects) on parasite clear-
ance are summarized in Table 2. The Y-axis intercept
(parasite load at admission) was not dependent on the
treatment mode (quinine or artesunate) but, as expected,
depended significantly on whether or not patients were
subjected to ET. This difference is fully explained
(Table 1) by the significantly higher parasite loads on ad-
mission in patients receiving ET than in patients not
receiving ET (mean (95% CI) parasite count 396,568
(298,231-494,906) vs 122,567 (91,456-153,678 asexual
parasites per μL) respectively, p value <0.0001). In con-
trast, in the model that estimates the parasite clearance
rate, the slope of the elimination curve significantly
improved when the treatment modality (quinine or
artesunate) was added as a random factor but not when
adding adjunctive treatment by ET or not.
Table 1 General characteristics of patients with imported severe P. falciparum malaria
Parenteral antimalarial treatment
without exchange transfusion
Parenteral antimalarial treatment
with exchange transfusion
(n=48) (n=39)
Quinine
monotherapy
Artesunate
monotherapy
Quinine + exchange
transfusion
Artesunate + exchange
transfusion
(Group I, n=38) (Group II, n=10) (Group III, n=23) (Group IV, n=16)
Demographics
Age, years note 1 39 (33–44) 42 (33–55) 48 (38–55) 52 (44–59)
Male, female, n (%) note 2 25 (66), 13 (34) 8 (80), 2 (20) 13 (57), 10 (43) 10 (63), 6 (37)
Weight, kg note 2 72 (62–81) 83 (75–86) 70 (60–90) 81 (72–87)
Ethnicity, n (%) note 2
Caucasian 12 (32) 5 (50) 14 (60) 7 (43)
African 20 (53) 5 (50) 5 (22) 6 (38)
Asian 4 (10) - 2 (9) 2 (13)
Other/unknown 2 (5) - 2 (9) 1 (6)
Continent of acquisition, n (%) note 2
Africa, [West-Africa] 34 (89), [27 (79)] 10 (100), [7 (70)] 21 (92), [17 (81)] 16 (100), [13 (81)]
Asia 3 (8) - 1 (4) -
South-America 1 (3) - 1(4) -
Vital signs on admission
Impaired consciousness (%), [GCS≤11] note 2 2 (5), [0 (0)] 1 (10), [0 (0)] 5 (22), [3 (60)] 3 (19), [1 (100)]
Body temperature, °C note 2 38.6 (38.2-40.1) 39.1 (38.3-39.6) 38.2 (37.0-39.8) 38.9 (37.7-39.8)
Pulse rate, beats per minute note 2 100 (90–113) 96 (90–116) 101 (91–113) 105 (100–116)
Systolic blood pressure, mm Hg note 2 120 (113–129) 118 (111–135) 113 (95–120) 125 (100–132)
Laboratory data on admission
Parasite load, parasites/μL note 1 111,650
(35,750-185,325)
74,000
(41,400-142,350)
357,000
(162,000-514,000)
313,500
(151,950-536,675)
Schizontaemia, n (%) note 3 11 (29) 2 (20) 14 (61) 12 (75)
Serum creatinine, μmol/L note 4 97 (78–114) 103 (85–124) 121 (95–159) 120 (88–163)
Plasma lactate, mmol/L note 5 1.8 (1.5-2.7) 2.3 (2.0-2.8) 2.3 (1.8-3.6) 3.0 (1.9-4.2)
Severe malaria (WHO 2010), n (%) note 1 14 (37) 3 (30) 23 (100) 16 (100)
Outcome
Duration hospitalisation, days note 6 6 (1–14)& 5 (4–5) 9 (3–19) 9 (6–11)
Hemodialysis, n (%) note 7 0 (0) 0 (0) 2 (9) 3 (19)
Mechanical ventilation, n (%) note 7 0 (0) 0 (0) 2 (9) 2 (13)
Survival, n (%) note 2 38 (100) 10 (100) 23 (100) 15 (94)^
Data are expressed as median (interquartile range) values or as indicated otherwise. GCS = Glasgow Coma Scale; & Comparison of quinine versus artesunate
treatment: p=0.0037.
All notes given in superscript relate to the statistical analysis of all quinine and artesunate monotherapies (n=48) versus all regimens containing exchange
transfusion (n=39). note 1 p<0.0001; note 2 p= not significant; note 3 p<0.0005; note 4 p<0.005; note 5 p<0.01; note 6 p<0.001; note 7 p<0.05. ^ One patient
succumbed to a suspected pulmonary embolism 8 days after complete parasite clearance.
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The parasite clearance times according to mixed ef-
fects model are shown in Figure 2 and Table 3. PCTs
were significantly shorter after administration of arte-
sunate as compared with quinine. In the mixed effects
model the institution of ET did not improve the model,
i.e. ET did not contribute significantly to parasite clear-
ance. Interestingly, the same conclusions were also
reached when data were analysed with the two-group
approach model as advocated by the WWARN working
group. Even though the WWARN model resulted in
somewhat shorter treatment-related parasite clearance
times (Additional file 1) than estimated with a mixed
model, parasite clearance rate and in particular parasite
elimination half-life was again significantly shorter in
artesunate-treated patients than in quinine-treated pa-
tients (3.7 (95% CI 3.2-4.2) hours versus 6.6 (95% CI 6.1-
7.2) hours, p value <0.0001, Additional files 2 and 3).
Although Additional file 1 suggests that with the
WWARN analysis, ET may have some beneficial effect
on parasite clearance when the patient is treated with
quinine, the differences in mean elimination half life
between patients receiving quinine and ET (6.3 (95%
CI 5.4-7.2) hours) did not differ significantly from pa-
tients treated with quinine only (6.8 (95% CI 6.1-7.6)
hours, p = 0.6105). However, at some time points
significant differences were observed in favour of
quinine plus ET (PCT90 and PCT95) but not at PCT50
and PCT99 (Additional file 1).
Discussion
The results of this retrospective follow-up study indicate
that parasite clearance is more rapid for adult travellers
with severe falciparum malaria when they are treated
with artesunate than with quinine. Manual exchange
transfusion does not significantly contribute to parasite
clearance. These conclusions were drawn irrespective of
the analysis method used to estimate parasite clearance.
The parasite clearance times associated with artesunate
and quinine found in the present study in largely non-
immune travellers are compatible with those found in
field trials in endemic regions [24]. Currently, there is no
evidence for artesunate resistance in returning travellers,
which may be due that the majority of P. falciparum
infections was acquired in Africa where artesunate resist-
ance has not been described yet [25] opposed to emerging
artesunate resistance in South East Asia [26].
Since its introduction in 1974 [27], ET has remained a
controversial adjunct therapy for the treatment of severe
malaria. Exchange transfusion has successfully been used
as an adjunct therapy in malaria patients for rapid re-
duction of parasite burden in patients with hyperpara-
Figure 1 Crude data of the parasite clearance curves of
patients with imported malaria treated with intravenous
artesunate or quinine with or without exchange transfusion.
Table 2 Mixed effects modelling of the time course of the
parasite count in severe P. falciparum malaria
Parameter Estimate SE P-value
Y-axis intercept 5.224 0.102 <0.001
(log initial parasitaemia (LogP0) /μl)
Adjunct treatment −0.466 0.124 <0.001 §
(no exchange transfusion)
Treatment mode −0.146 0.137 0.289
(artesunate)
Parasite elimination rate constant (/h) −0.041 0.002 <0.001
(parasite clearance time)@
Adjunct treatment 0.004 0.003 0.242 #
(no exchange transfusion)
Treatment mode (artesunate) −0.023 0.004 <0.001*
There was no difference in initial parasitaemia between artesunate and
quinine patients, but §patients receiving exchange transfusion had higher
initial parasitaemia than patients not receiving exchange transfusion.
*artesunate had a significant effect on parasite clearance compared to quinine,
#while institution of exchange transfusion had no significant effect on parasite
clearance. @fixed effect: LogP ~ t , which reads as LogP(t) = Intercept + k.LogP0.
Figure 2 Parasite clearance curves of log transformed data
according to linear mixed model analysis.
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sitaemia, improvement of the rheological characteristics
of blood and removal of toxic byproducts. On the other
hand, its efficacy has never been properly demonstrated
in a sufficiently powered randomized controlled trial. In
a meta-analysis comparing severe malaria patients who
received either adjunct ET or anti-malarial chemother-
apy alone, no difference in survival rates was found, al-
though patients who received exchange transfusion were
more critically ill and had significantly higher parasit-
aemia levels [8]. Furthermore, ET may come with signifi-
cant health risks such as fluid overload, hypotension,
cerebral hemorrhage, febrile and allergic reactions,
metabolic disturbances and transmissible infections [28].
However, with the use of a standardized but foremost
isovolumetric manual exchange protocol these adverse
events were rarely observed [16].
It should be noted that the parasite clearance times
may completely differ for exchange procedures using
automated erythrocytapheresis. Whereas in a manual ET
procedure approximately half of the blood volume is
exchanged in 5 hours with an anticipated 40% reduction
of parasite load in case of an isovolumetric exchange [16],
an entire blood volume can be exchanged in 1.5 hours
with automated erythrocytapheresis [29]. In addition, au-
tomated erythrocytapheresis may have further advantages
over manual exchange procedures in terms haemo-
dynamic stability, preservation of plasma and cellular
components, efficiency and speed. However, it would only
be easily available in specialized centers. In contrast,
manual exchange procedures can be executed without
delay once a diagnosis of severe disease has been made,
even in hospitals without direct access to automated
RBC exchange.
Irrespective of the exchange procedure applied, ex-
changing blood only removes circulating parasite stages
from the circulation; a large proportion of parasitized
RBCs may not be exchanged as long as they remain se-
questered in the microvasculature of vital organs. In
addition, exchange procedures may have additional ad-
vantages over automated RBC exchange by removing the
burden of toxins and other products arising from the
parasite and host response. This may explain the benefi-
cial effect of plasma exchange in severe malaria observed
in some reports [30]. Moreover, and probably under-
estimated, as compared to healthy subjects, parasitized
RBCs but also uninfected RBCs are considerably less de-
formable in severe malaria [31]. Replacing less deform-
able RBCs by fresh RBC is a biologically plausible
explanation for potential beneficial effects of exchange
transfusion. Although there is currently no consensus in
treatment protocol in terms of indication and volume to
be exchanged, exchange transfusion was usually initiated
in patients with hyperparasitaemia (either >30% or >
10% in the presence of other severe complications).
Since the rapid reduction of parasite burden is mostly
attributable to anti-malarial treatment, in particular
artesunate, ET should not be installed for reasons of
aiding in parasite clearance, at least not with manual
exchange transfusion procedures.
This study is based on a single-centre experience with
standardized procedure and well-equipped intensive care
facilities. It has the advantage of standardized and uni-
form procedures but the disadvantage of a relatively
small sample size. The treatment protocol reserves ET
for the most severely ill patients with hyperparasitaemia
and/or organ damage and this may have led to selection
bias with diminishing effect modification. However,
within the treatments groups subjected to ET (groups III
and IV), there were no differences at baseline between
artesunate and quinine treated patients and this suggest
that a proper comparison is allowed. A prospective com-
parative trial in industrialized non-endemic countries is
deemed not feasible because the number of eligible pa-
tients suffering from severe imported P. falciparum mal-
aria is small, and to obtain a meaningful outcome, even
in a multicentre-based study, it would require many
years. It is not expected that high-level of evidence will
become available soon. Since this study focused on para-
site clearance alone, no conclusions can be drawn on
other proposed beneficial mechanisms of exchange
transfusion like removal of parasite toxins and improve-
ment of haemorrheology.
Table 3 Parasite clearance times according to mixed model analysis of 84 malaria patients receiving parenteral
anti-malarial treatment
Treatment mode Quinine (n = 59) Artesunate (n = 25)
Adjunct treatment No exchange transfusion
(n = 37)
Exchange transfusion
(n = 22)
No exchange transfusion
(n = 9)
Exchange transfusion
(n = 16)
PCT 50% (h) 8.0 (7.2-8.8) 7.3 (6.5-8.2) 5.0 (4.4-5.6) 4.7 (4.2-5.2)
PCT 90% (h) 26.6 (23.9-29.4) 24.3 (20.7-28.0) 16.6 (14.6-18.7) 15.7 (14.1-17.3)
PCT 95% (h) 34.6 (31.0-38.2) 31.7 (28.8-34.5) 21.6 (17.5-25.7) 20.4 (18.3-22.5)
PCT 99% (h) 53.2 (47.7-58.8) 48.7 (43.0-54.3) 33.2 (30.5-35.9) 31.4 (28.1-34.6)
Data are given as mean (95% confidence interval).
Three of 87 patients were excluded from analysis because of an initial parasitaemia lower than 1,000 parasites per μL (Quinine n = 1) or because the last
parasitaemia exceeded 1,000 parasites per μL (Quinine plus ET n = 1; artesunate n = 1), as defined by Flegg et al. [17].
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Conclusion
When severe P. falciparum malaria is treated with intra-
venous quinine, there may be a small beneficial effect of
manual ET on parasite clearance. However, there is no
benefit of ET on parasite clearance in artesunate-treated
individuals. Based on these findings manual exchange
transfusion is no longer recommended for patients with
severe P. falciparum malaria who are being treated with
intravenous artesunate.
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